Ophthalmic compositions with improved dessication protection and retention

Abstract

The present invention relates to artificial tear compositions and ophthalmic compositions suitable for drug delivery. In one embodiment of the present invention, the compositions comprise a galactomannan polymer such as guar or hydroxypropyl guar, hyaluronic acid, and a cis-diol such as sorbitol. In a preferred embodiment, the compositions also comprise a borate compound.

The invention claimed is: 
     
       1. An ophthalmic composition comprising 0.1 to 0.2 w/v % hydroxylpropyl guar, 0.13 to 0.17 w/v % hyaluronic acid, 1.0 to 2.0 w/v % cis-diol and a pharmaceutically active compound, wherein the cis-diol is sorbitol and the pharmaceutically active compound is selected from the group consisting of a glaucoma therapeutic, a pain reliever, an anti-inflammatory medication, an anti-allergy medication, a post- surgical antihypertensive agent, a dry eye therapeutic, an anti-infective, and an anti-microbial, for the treatment of ophthalmic diseases. 
     
     
       2. The ophthalmic composition according to  claim 1  comprising 0.17 to 0.18 w/v % hydroxylpropyl guar, 0.13 to 0.17 w/v % sodium hyaluronate and 1.0 to 2.0 w/v % w/v % sorbitol. 
     
     
       3. The ophthalmic composition according to  claim 1  further comprising a borate, wherein said borate is boric acid. 
     
     
       4. The ophthalmic composition according to  claim 1  further comprising a demulcent selected from the group consisting of: glycerin, polyvinyl pyrrolidone, polyethylene oxide, polyethylene glycol, propylene glycol, polyacrylic acid, and combinations thereof. 
     
     
       5. The ophthalmic composition according to  claim 4 , wherein said demulcent is propylene glycol, or polyethylene glycol. 
     
     
       6. The ophthalmic composition according to  claim 1 , wherein the glaucoma therapeutic is betaxolol, timolol, pilocarpine, or a carbonic anhydrase inhibitor. 
     
     
       7. The ophthalmic composition according to  claim 1 , wherein the post-surgical antihypertensive agent is para-amino clonidine. 
     
     
       8. The ophthalmic composition according to  claim 1 , wherein the anti-infective medication is ciprofloxacin, moxifloxacin, or tobramycin. 
     
     
       9. The ophthalmic composition according to  claim 1 , wherein the anti-allergy medication is an H1/H4 inhibitor, an H4 inhibitor, or olopatadine. 
     
     
       10. The ophthalmic composition according to  claim 1 , wherein the dry eye therapeutic is a PDE4 inhibitor. 
     
     
       11. The ophthalmic composition according to  claim 1 , wherein the anti-inflammatory medication is naproxen, diclofenac, nepafenac, suprofen, ketorolac, tetrahydrocortisol, or dexamethasone. 
     
     
       12. The ophthalmic composition according to  claim 1 , wherein the pain reliever is prostaglandin, or a dopaminergic antagonist.